J. Rossouw, G. Anderson, R. Prentice, A. Lacroix, C. Kooperberg et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, Jama, vol.288, pp.321-333, 2002.

G. Anderson, M. Limacher, A. Assaf, T. Bassford, S. Beresford et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, Jama, vol.291, pp.1701-1712, 2004.

J. Haas, C. Kaplan, E. Gerstenberger, and K. Kerlikowske, Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results, Annals of Internal Medicine, vol.140, issue.3, pp.184-188, 2004.
DOI : 10.7326/0003-4819-140-3-200402030-00009

H. Nelson and . Menopause, Menopause, The Lancet, vol.371, issue.9614, pp.760-770, 2008.
DOI : 10.1016/S0140-6736(08)60346-3

M. Cushman, L. Kuller, R. Prentice, R. Rodabough, B. Psaty et al., Estrogen Plus Progestin and Risk of Venous Thrombosis, JAMA, vol.292, issue.13, pp.1573-1580, 2004.
DOI : 10.1001/jama.292.13.1573

J. Curb, R. Prentice, P. Bray, R. Langer, L. Van-horn et al., Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus, IMS updated recommendations on postmenopausal hormone therapy, pp.772-780181, 2006.
DOI : 10.1001/archinte.166.7.772

W. Utian, D. Archer, G. Bachmann, C. Gallagher, F. Grodstein et al., Estrogen and progestogen use in postmenopausal women position statement of The North American Menopause Society, Menopause, vol.15, pp.584-602, 2008.

M. Canonico, G. Plu-bureau, G. Lowe, and P. Scarabin, Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis, BMJ, vol.336, issue.7655, pp.1227-1231, 2008.
DOI : 10.1136/bmj.39555.441944.BE

URL : https://hal.archives-ouvertes.fr/inserm-01142884

J. Miller, B. Chan, and H. Nelson, Postmenopausal Estrogen Replacement and Risk for Venous Thromboembolism, Annals of Internal Medicine, vol.136, issue.9, pp.680-690, 2002.
DOI : 10.7326/0003-4819-136-9-200205070-00011

V. Beral, E. Banks, and G. Reeves, Evidence from randomised trials on the long-term effects of hormone replacement therapy, The Lancet, vol.360, issue.9337, pp.942-944, 2002.
DOI : 10.1016/S0140-6736(02)11032-4

P. Scarabin, E. Oger, and G. Plu-bureau, Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk, The Lancet, vol.362, issue.9382, pp.428-432, 2003.
DOI : 10.1016/S0140-6736(03)14066-4

URL : https://hal.archives-ouvertes.fr/hal-01026273

M. Canonico, E. Oger, G. Plu-bureau, J. Conard, G. Meyer et al., Hormone therapy and
URL : https://hal.archives-ouvertes.fr/inserm-01148705

A. Fournier, F. Berrino, E. Riboli, V. Avenel, and F. Clavel-chapelon, venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study Breast cancer risk in relation to different types of hormone replacement therapy in the E3N- EPIC cohort, Circulation. Int J Cancer, vol.115114, issue.14, pp.840-845448, 2005.

A. Fournier, A. Fabre, S. Mesrine, M. Boutron-ruault, F. Berrino et al., Use of different postmenopausal hormone therapies and risk of histology-and hormone receptor-defined invasive breast cancer Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society, J Clin Oncol. Menopause, vol.2610, issue.16, pp.1260-1268113, 2003.

T. Simon, B. Yon-de-jonage-canonico, M. Oger, E. Wahl, D. Conard et al., Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism, Journal of Thrombosis and Haemostasis, vol.85, issue.1, pp.71-76, 2006.
DOI : 10.1046/j.1365-2265.1997.2601068.x

URL : https://hal.archives-ouvertes.fr/hal-00688975

M. Gomes and S. Deitcher, Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy, Archives of Internal Medicine, vol.164, issue.18, pp.1965-1976, 2004.
DOI : 10.1001/archinte.164.18.1965

E. Daly, M. Vessey, M. Hawkins, J. Carson, P. Gough et al., Risk of venous thromboembolism in users of hormone replacement therapy, The Lancet, vol.348, issue.9033, pp.977-980, 1996.
DOI : 10.1016/S0140-6736(96)07113-9

S. Perez-gutthann, G. Rodriguez, L. Castellsague, J. , D. Oliart et al., Hormone replacement therapy and risk of venous thromboembolism: population based case-control study, BMJ, vol.314, issue.7083, pp.796-800, 1997.
DOI : 10.1136/bmj.314.7083.796

J. Douketis, J. Julian, C. Kearon, D. Anderson, M. Crowther et al., Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study, Journal of Thrombosis and Haemostasis, vol.83, issue.5, pp.943-948, 2005.
DOI : 10.1001/jama.292.13.1573

H. Jick, L. Derby, M. Myers, C. Vasilakis, K. Newton et al., Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis, Lancet. Jama, vol.348292, issue.23, pp.981-9831581, 1996.

M. Vickers, A. Maclennan, B. Lawton, D. Ford, J. Martin et al., Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications, Bmj. Lancet, vol.335354, p.1610, 1999.

R. Virchow, Phlogose und Thrombose in Gefäßsystem. Gesammelte Abhandlungen zur Wissenschaftlichem Medizin, 1856.

A. Cano and W. Van-baal, The mechanisms of thrombotic risk induced by hormone replacement therapy, Maturitas, vol.40, issue.1, pp.17-38, 2001.
DOI : 10.1016/S0378-5122(01)00270-5

P. Scarabin, M. Alhenc-gelas, G. Plu-bureau, P. Taisne, R. Agher et al., Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women : A Randomized Controlled Trial, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.17, issue.11, pp.3071-3078, 1997.
DOI : 10.1161/01.ATV.17.11.3071

K. Koh, M. Horne, and R. Cannon, Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women, Thromb Haemost, vol.82, pp.626-633, 1999.

H. Teede, B. Mcgrath, J. Smolich, E. Malan, D. Kotsopoulos et al., Postmenopausal Hormone Replacement Therapy Increases Coagulation Activity and Fibrinolysis, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.20, issue.5, pp.1404-1409, 2000.
DOI : 10.1161/01.ATV.20.5.1404

URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=

G. Lowe, M. Upton, A. Rumley, A. Mcconnachie, O. Reilly et al., Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey, Thromb Haemost, vol.86, pp.550-556, 2001.

E. Oger, M. Alhenc-gelas, K. Lacut, M. Blouch, N. Roudaut et al., Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women, Arterioscler Thromb Vasc Biol. Arterioscler Thromb Vasc Biol, vol.2323, issue.33, pp.1671-16761116, 2003.

M. Alhenc-gelas, G. Plu-bureau, S. Guillonneau, J. Kirzin, M. Aiach et al., Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives, Journal of Thrombosis and Haemostasis, vol.103, issue.Suppl. 1, pp.1594-1600, 2004.
DOI : 10.1111/j.1538-7836.2004.00894.x

J. Conard, A. Basdevant, J. Thomas, E. Ochsenbein, C. Denis et al., Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women, Fertil Steril. Thromb Haemost. J Intern Med, vol.6483251, issue.37, pp.957-96229, 1995.

P. Collins, M. Flather, B. Lees, R. Mister, A. Proudler et al., Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study, European Heart Journal, vol.27, issue.17, pp.2046-2053, 2006.
DOI : 10.1093/eurheartj/ehl183

L. Norris, J. Brosnan, J. Bonnar, J. Conard, C. Kluft et al., Inhibitors and activation markers of the haemostatic system during hormone therapy: a ATVB R2, p.25

K. Cohen-solal, E. Milgrom, and M. Finet, mg)/ trimegestone Progesterone receptor expression in human saphenous veins, Thromb Haemost. Circulation, vol.10092, issue.40, pp.253-2602975, 1995.

D. Fraser, M. Padwick, M. Whitehead, J. White, T. Ryder et al., The effects of the addition of nomegestrol acetate to post-menopausal oestrogen therapy Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits, Maturitas. Menopause, vol.119, issue.42, pp.21-346, 1989.

A. Eilertsen, E. Qvigstad, T. Andersen, L. Sandvik, and P. Sandset, Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation, Maturitas, vol.55, issue.3, pp.278-287, 2006.
DOI : 10.1016/j.maturitas.2006.04.012

E. Oger and M. Boutron-ruault, Sylvie Mesrine Manuscript writing: Françoise Clavel-Chapelon

E. The and . Cohort, Characteristics Population (n=80,308)